Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911791 | 1.00 | CHRNB2 (0.39) | CHRNB2CHRNA4HCRTR1HCRTR2BRD4 | |
| SCHEMBL3922331 | 0.91 | CHRNB2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL3918221 | 0.91 | CHRNB2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL4917066 | 0.81 | IRAK4 (0.36) | CHRNB2CHRNA4BRD4RET | |
| SCHEMBL4918812 | 0.81 | IRAK4 (0.36) | CHRNB2CHRNA4BRD4RET | |
| SCHEMBL4917420 | 0.80 | HCRTR1 (0.35) | HCRTR1HCRTR2BRD4ABL1TDO2 | |
| SCHEMBL4920078 | 0.80 | CHRNB2 (0.34) | CHRNB2CHRNA4RET | |
| SCHEMBL4917368 | 0.80 | CHRNB2 (0.34) | CHRNB2CHRNA4RET | |
| SCHEMBL4911781 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4RET | |
| SCHEMBL4911776 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| EP-1863797-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100461-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | IGF1R, IGFBP1, IGFBP2 | CHRNB2 4588/4885CHRNA4 4717/4885HCRTR1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.